Autor(es):
Marques da Silva, P ; Sequeira Duarte, J ; von Hafe, P ; Gil, V ; Nunes de Oliveira, J ; de Sousa, G
Data: 2018
Identificador Persistente: http://hdl.handle.net/10400.17/3365
Origem: Repositório do Centro Hospitalar de Lisboa Central, EPE
Assunto(s): Biomarkers; Blood Chemical Analysis; Cardiovascular Diseases; Consensus; Dyslipidemias; Fasting; Humans; Lipids; Lipoproteins; Portugal; Predictive Value of Tests; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; HSM MED
Descrição
Even with the improvement in lifestyle interventions, a better control of cardiovascular (CV) risk factors, and improvements in CV outcomes, cardiovascular disease (CVD) still persists as the leading cause of morbidity and mortality in Portugal and Europe. Atherogenic dyslipidaemias, namely hypercholesterolaemia, have a crucial and causal role in the development of atherosclerotic CVD. The clinical approach of a patient with dyslipidaemia involves a watchful diagnosis, sustained in lipid and lipoprotein laboratory procedures, which must be harmonized and standardized. Standardization of lipid test results and reports, incorporating the total CV risk and the respective target and goals of treatment approach, guarantees that clinical guidelines and good clinical practices are followed and respected, increasing the reliability of lipid disorders screening, producing more accurate diagnoses and CV risk stratification, and improving the CV prevention and the achievement the desirable treatment goals.
